<DOC>
	<DOC>NCT02823743</DOC>
	<brief_summary>The aim of this study is to examine whether treatment with 75 mg aspirin daily compared with placebo could reduce the risk for a new miscarriage. The treatment starts when the pregnancy is detected on transvaginal ultrasound (around gestational week 6+) and continues to week 35/36. The study is a single center, randomized, placebo-controlled, double blind and stratified for age. 400 participants with the diagnosis idiopathic recurrent abortion are enrolled, 200 in each arm aspirin / placebo.</brief_summary>
	<brief_title>RECAB-ASA; Treatment of Recurrent Abortion With Aspirin</brief_title>
	<detailed_description />
	<mesh_term>Abortion, Habitual</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>recurrent abortion (≤ 3 consecutive abortions in first trimester) unknown etiology after workup willingness to be randomized previous participation in the study known cause of recurrent abortion, requiring specific management age ≥ 40 BMI above 35 IVF pregnancy if the reason for IVF was recurrent spontaneous abortion ongoing treatment with aspirin for other reason Sjoegren syndrome</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent pregnancy loss, Habitual abortion</keyword>
</DOC>